ArticleScientific reports2025
Potential glutamine metabolism-related biomarkers were identified in osteoarthritis by bioinformatics.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Osteoarthritis (OA) is a prevalent joint disorder. It is of great importance to identify efficacious therapeutic targets and biomarkers for the treatment of inflammatory joint diseases and the effective management of their condition. Glutamine metabolism is pivotal in regulating chondrocyte function, maintaining bone homeostasis and modulating the inflammatory response. This study aimed to identify glutamine metabolism-related genes that may serve as potential biomarkers for OA. The OA transcriptome dataset and the glutamine metabolism-related genes were obtained. Subsequently, consistency clustering was employed to differentiate between different disease types for the glutamine metabolism-related genes in the OA transcriptome dataset. Furthermore, differential expression analysis was conducted, and functional enrichment analysis was employed to elucidate the underlying mechanisms. A protein-protein interaction (PPI) network was constructed and candidate key genes were identified through Cytoscape's 7 algorithms. Valuation of the diagnostic ability of OA and prediction of transcription factors (TFs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs) that were related. Subsequently, drug prediction and molecular docking were conducted. An OA mice model and cell model were established using the DMM and IL-1β methods, respectively, were employed to verify the expression. 1018 differentially expressed genes (DEGs1) were obtained in the OA transcriptome dataset. Subsequently, based on glutamine metabolism-related genes, the transcriptome dataset genes between two subtypes were further 385 differentially expressed genes (DEGs2) were obtained. An intersection of the DEGs1 and the DEGs2 revealed 102 intersecting genes, which were considered candidate genes. LRRFIP1 and MFSD11 as the key genes according to Cytoscape's 7 algorithms and expression levels verification, and with a better OA diagnostic ability. Subsequently, the OA mice model and cell model were established successfully, LRRFIP1 and MFSD11 both had a lower expression level. Glutamine metabolism-related genes LRRFIP1 and MFSD11 may be potential biomarkers for diagnosing and treating OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.